BACKGROUND: @entity1005 ( @entity1005 ) tends to follow a chronic and treatment resistant course. Avoidance and numbing are symptoms associated with chronicity and impaired life quality. As @entity12210 (DCS) can facilitate extinction of conditioned fear, we aimed to investigate the efficacy and tolerability of DCS for the treatment of numbing and avoidance in chronic @entity1005 . MATERIALS AND METHODS: This was an 11-week, double-blind, cross-over trial conducted in 2012 and 2013, in out- @entity1 University psychiatry clinics. The studied population was selected randomly among outpatients with chronic combat-related @entity1005 (based on DSM-IV-TR criteria for chronic @entity1005 ), who were males over 18 and <65 years of age (n = 319). Seventy six eligible @entity1 were randomly assigned to two groups. @entity1 entered a 1-week run-in period. The groups received either an add-on treatment of DCS (50 mg daily), or placebo (4-week). After a 2-week washout, the groups received cross-over treatments (4-week). Clinical, paraclinical assessments, and clinician administered @entity1005 scale (CAPS) were performed at baseline, and at the end of the 1(st), 5(th), and 11(th) week. Side-effects were also evaluated. The overall number of avoidance and numbing symptoms, symptom frequency, and symptom intensity were measured separately. RESULTS: Neither frequency nor number of symptoms was significantly influenced. However, DCS treatment demonstrates a significant decrease in intensity of avoidance/numbing symptoms, and improvement in function (mean [standard error] = -4.2 [1.5], P = 0.008). Side-effects were not statistically remarkable. CONCLUSION: @entity12210 can help as an adjunctive treatment to alleviate numbing and avoidance in combat-related chronic @entity1005 .

XXXX for treatment of numbing and avoidance in chronic post traumatic stress disorder: A randomized, double blind, clinical trial.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity12210 :: ('CHEBI:74159', 'Chemical') :: ['D-cycloserine'] @entity1005 :: ('MESH:D013313', 'Disease') :: ['Posttraumatic stress disorder', 'PTSD']
@entity12210 :: (CHEBI:74159,Chemical) :: ['D-cycloserine']
